|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We constructed a Markov model in a hypothetical cohort of adult Asian patients with epilepsy in the United States being considered for carbamazepine to investigate the cost-effectiveness of two alternative strategies: (1) no HLA-B*1502 gene allele screening and using carbamazepine and (2) HLA-B*1502 gene allele screening and starting levetiracetam in the case of a positive screen.
|
31158306 |
2019 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 polymorphism and Tegretol<sup>®</sup>-induced serious cutaneous reactions in epilepsy: An updated systematic review and meta-analysis.
|
29685430 |
2018 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
A hybrid model of a decision tree and Markov model was developed to evaluate three strategies for treating newly diagnosed epilepsy among adults: (i) carbamazepine initiation without HLA-B*15:02 screening (current practice); (ii) universal HLA-B*15:02 screening prior to carbamazepine initiation; and (iii) alternative treatment [sodium valproate (VPA)] prescribing without HLA-B*15:02 screening.
|
28346659 |
2017 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, sufficient levels of evidence to justify routine use have been achieved for only a few tests (eg, major histocompatibility complex, class I, B, allele 1502 [HLA-B*1502] for carbamazepine in epilepsy and bipolar disorders); many findings are too preliminary or, when replicated, of low clinical relevance because of a small effect size.
|
27757065 |
2016 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the cost-effectiveness of the HLA-B*15:02 screening policy for the treatment of epilepsy in Hong Kong.
|
26888992 |
2016 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examined the significant association between carbamazepine (CBZ)-induced Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN) and HLA-B*15:02 in epilepsy patients of Han ethnicity living in northeastern China.
|
24399721 |
2013 |
|
Epilepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
An economic evaluation was carried out by using a decision tree and Markov models to examine the cost-utility of providing HLA-B*15:02 screening for all patients with either newly diagnosed epilepsy or neuropathic pain in the Thai setting.
|
23895569 |
2013 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore.
|
22955130 |
2012 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe the association of the HLA-B*1502 allele in 27 epilepsy patients (19 Malays, 8 Chinese) treated with carbamazepine (CBZ) at the UKM Medical Center (UKMMC), 6 with CBZ-Steven Johnson Syndrome (CBZ-SJS), 11 with CBZ-induced rash, 2 with suspected phenytoin-induced rash and 8 negative controls.
|
22053601 |
2011 |
|
Epilepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B*1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.
|
18627414 |
2009 |